Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Uterine Neoplasms × VMBP protocol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Neoplasms 1 Urologic Neoplasms 1 Kidney Neoplasms 1 Kidney Diseases 1 Endometrial Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma 1

Interventions

pembrolizumab 3 Paclitaxel 2 Carboplatin 2 sacituzumab govitecan 1 osimertinib 1 olaparib 1 ferumoxtran-10 1 dostarlimab 1 cobimetinib 1 VMBP protocol 1 Taxes 1 Immunoglobulin G 1 Imatinib Mesylate 1 D-methadone 1 Cisplatin 1 Bevacizumab 1 Axitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05559879 2025-05-04

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

University of Alabama at Birmingham

Phase 1/2 Recruiting

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡